Maze Therapeutics Appoints Drug Development Expert Richard Scheller, Ph.D., to its Board of DirectorsDownload PDF
SAN FRANCISCO, July 9, 2019 – Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Richard Scheller, Ph.D. has joined the company’s board of directors.
We are thrilled to welcome Richard to our board of directors…and we look forward to applying Richard’s broad drug development expertise to our programs.
“We are thrilled to welcome Richard to our board of directors given his distinguished academic career and accomplishments as a drug discovery and development leader,” said Jason Coloma, Ph.D., chief executive officer of Maze. “At Maze, we are focused on developing therapies in many disease areas utilizing various therapeutic approaches, and we look forward to applying Richard’s broad drug development expertise to our programs. I am excited to work with Richard as we continue to advance our drug discovery efforts focused on translating our insight of genetic modifiers to create new therapies.”
Dr. Scheller was previously the head of therapeutics and chief scientific officer at 23andMe. Prior to his role there, Dr. Scheller spent 14 years at Genentech where he was executive vice president of research and early development. He served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities. From 1982 to 2001, Dr. Scheller served on the faculty of Stanford University as a professor in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. In 2013, Dr. Scheller received the Albert Lasker Basic Medical Research Award for discoveries concerning the molecular machinery and regulatory mechanism that underlie the rapid release of neurotransmitters. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco. He has published more than 200 primary research papers during his career. Dr. Scheller holds a B.S. in biochemistry from the University of Wisconsin-Madison and a Ph.D. in chemistry from California Institute of Technology (Caltech).
“Maze’s approach and platform bring together a wealth of human genetics insights and an unparalleled knowledge of genomics in order to discover and develop new medicines. I have been very impressed by the science and technology behind the company, and, coupled with the expert team the company has built, I am excited to partner with them as Maze grows,” said Dr. Scheller.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for a number of genetically defined diseases. Maze is focused on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics and an array of drug discovery approaches. The Maze platform reveals modifier genes that confer protection, and provides deeper understanding of the target biology and how these targets can be best targeted with drug therapies. Maze was launched in 2019 by Third Rock Ventures, with funding from ARCH Venture Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Maze is based in South San Francisco. For more information please visit http://mazetx.com.
Katie Engleman, 1AB